UroGen Pharma Ltd. (NASDAQ:URGN) Receives $38.20 Average PT from Brokerages

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $38.20.

A number of equities research analysts have recently weighed in on URGN shares. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research report on Monday, March 10th. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective on the stock. Finally, HC Wainwright decreased their price objective on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a report on Tuesday, March 11th.

Insiders Place Their Bets

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Schoenberg sold 4,551 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. Toronto Dominion Bank purchased a new stake in UroGen Pharma during the 4th quarter valued at $18,628,000. Acorn Capital Advisors LLC purchased a new stake in UroGen Pharma during the fourth quarter valued at $16,149,000. Nantahala Capital Management LLC bought a new position in UroGen Pharma in the fourth quarter valued at about $14,608,000. Vestal Point Capital LP boosted its position in UroGen Pharma by 307.5% in the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after purchasing an additional 1,230,000 shares during the last quarter. Finally, Rosalind Advisors Inc. bought a new stake in shares of UroGen Pharma during the 4th quarter valued at about $9,266,000. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Trading Up 0.7 %

Shares of URGN opened at $11.53 on Friday. The stock has a market capitalization of $531.46 million, a P/E ratio of -3.66 and a beta of 1.12. UroGen Pharma has a twelve month low of $9.03 and a twelve month high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The firm has a fifty day simple moving average of $10.47 and a two-hundred day simple moving average of $11.60.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. On average, research analysts anticipate that UroGen Pharma will post -3.12 EPS for the current year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.